Vofatamab

沃凡妥单抗

Report date: 2022/11/25 16:34:12

Base Information

Drug NameVofatamab
Drug Alias NameAnti FGR3MFGR-1877AVofatamab - Rainier TherapeuticsB-701MFGR-1877A +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 3
Therapy Area/IndicationsSolid tumoursUrinary Bladder DiseasesUrologic Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBioclin Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech IncRainier Therapeutics Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursUrinary Bladder DiseasesUrologic Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksN/A